NCT04576143View on ClinicalTrials.gov

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

September 20, 2020

Primary Completion Date

June 20, 2023

Study Completion Date

September 20, 2027

Conditions
HER2-negative Breast CancerNeoadjuvant Chemotherapy
Interventions
DRUG

Epirubicin

i.v. 90 mg/m2

DRUG

Cyclophosphamid

i.v. 600 mg/m2

DRUG

Docetaxel

i.v. 100 mg/m2

DRUG

Paclitaxel

i.v. 175 mg/m2

Trial Locations (1)

310000

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Women's Hospital School Of Medicine Zhejiang University

OTHER

collaborator

Changxing People's Hospital

OTHER

collaborator

Zhejiang Provincial People's Hospital

OTHER

collaborator

Hangzhou First People's Hospital, School of Medicine, Zhejiang Universiry

UNKNOWN

collaborator

Huizhou Municipal Central Hospital

OTHER

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT04576143 - Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer | Biotech Hunter | Biotech Hunter